The company discontinued developing emugrobart after two studies showed the drug didn’t achieve intended outcomes.

The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.

Chris Stoelhorst, Chairman of MARS Bioimaging, said: “With FDA clearance, we can now scale clinical adoption of our scanners ...

Mirecule, Inc., a leader in Antibody RNA Conjugate (ARC) therapeutics targeting rare neuromuscular diseases, today announced an expansion of its strategic collaboration with Sanofi. This collaboration ...

Novartis AG faces major patent expiries but is buying pipeline assets to sustain growth. Click for this NVS update.

What is SMA? The rare genetic condition that Jesy Nelson’s twin daughters have - Former Little Mix star revealed her twin ...

The ACSM released new resistance training guidelines to improve muscle strength, size, and performance. medical News today ...

Indiana Orthopedic Institute is expanding patient access to expert musculoskeletal care to the southside area with the ...

Musculoskeletal disorders are a primary cause of disability worldwide, especially in aging societies like Japan. As ...

We have identified a macrophage population "Mrep" that plays an essential role in muscle repair. However, in Fibrodysplasia ...

Leni Forrester, 2, has Sanfilippo Syndrome, a rare genetic condition often described as childhood dementia - and popstar Jesy ...

Pedaling through 120 miles of desolate Northern California country roads, I was humbled by many things — the unforgiving bite ...